MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies.
MnSOD-K68-Ac 重新编程 ER 乳腺恶性肿瘤中的谱系可塑性开关/干性。
基本信息
- 批准号:10817556
- 负责人:
- 金额:$ 5.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-09 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AcetylationAddressAllelesAllograftingAntineoplastic AgentsBioenergeticsBreastBreast Cancer CellBreast CarcinogenesisCDK4 geneCell SurvivalCellsCellular Metabolic ProcessChemicalsClustered Regularly Interspaced Short Palindromic RepeatsCombined Modality TherapyComplexDependenceDevelopmentDrug Metabolic DetoxicationEndocrineEnzyme InductionEnzymesEpigenetic ProcessEquilibriumEstrogen ReceptorsEstrogen TherapyEstrogen receptor positiveExhibitsFastingFatty acid glycerol estersFulvestrantGenesGeneticHumanImpairmentImplantIn VitroInfectionKnock-in MouseLaboratoriesLysineMCF7 cellMalignant NeoplasmsMammary NeoplasmsMedicineMetabolicMetabolic stressMetabolismMitochondriaModelingMolecularMouse Mammary Tumor VirusMusNatureNutrientOncogenicOxygenPathway interactionsPeroxidasesPhenotypePhysiologicalPhysiologyPlayProcessProgression-Free SurvivalsPropertyProteinsReactive Oxygen SpeciesReceptor SignalingRecurrenceResearchResearch ProposalsResistanceResistance developmentRiskRoleSOD2 geneSamplingSignal TransductionStainsSubgroupSuperoxidesT47DTamoxifenTestingTherapeuticTumor Suppressor ProteinsTumor stageTumor-DerivedWomanXenograft procedurebreast malignanciescancer cellcarcinogenesiscarcinogenicitycell growthexperimental studyfeedinggenomic datahigh riskhormone therapyhuman modelin vivoin vivo Modelinhibitorknock-downmalignant breast neoplasmmammarymimeticsmitochondrial metabolismmolecular markermonomermouse modelmutantneoplastic cellnovel therapeutic interventiononcogene addictionpatient derived xenograft modelpatient subsetsprogramsstemnesstargeted agenttherapy resistanttissue culturetissue/cell culturetumortumor initiationtumorigenesistumorigenic
项目摘要
Summary - A fundamental theme in personalized cancer medicine is to identify specific subgroups
of patients, based on molecular biomarkers and/or tumor signatures, which will subsequently benefit
from new therapeutic strategies, including targeted agents. An important, and longstanding, example
of this concept is the dependency of a subgroup of breast malignancies on the estrogen receptor
(ER) as well as the ER signaling axis. In this regard, there is a subgroup of women with ER+ luminal
B human breast malignancies that exhibit a significant risk of recurrence due to the development of
resistance to endocrine therapy, including Tamoxifen. To address this, there is an ongoing search
to define the pathways or molecular mechanism(s) leading to the resistance to endocrine therapy. A
second significant theme in cancer medicine is based on the idea of “oncogene addiction”, a
phenomenon that implies while tumors contain multiple genetic, epigenetic, signaling, and metabolic
abnormalities and despite this tumor complexity, cell growth and survival can often be impaired by
the targeting of a single driver gene/protein.
As such, the phenomenon of oncogene addiction
in
specific cancers, including luminal B breast carcinogenesis, provides a scientific rational to identify
carcinogenic drivers in the process luminal B resistance to endocrine therapies. Metabolic stress,
due to aberrant reactive oxygen ROS levels, is a hallmark of cancer that disrupts mitochondrial
physiology and metabolism leading to an oncogenic addition-like phenotype and resistance to
endocrine therapy. Based on these observations, it is proposed that K68 acetylation (K68-Ac)
promotes a newly discovered monomeric form of MnSOD, distinct from the established ROS
detoxification role of tetrameric MnSOD, reprograms cellular and mitochondrial metabolism leading
to oncogenic and tumor resistance phenotype. Finally, will targeting the MnSOD-K68-Ac axis, using
a chemical MnSOD mimic (GC4419), convert endocrine resistance tumors to a sensitive phenotype?
总结-个性化癌症医学的一个基本主题是确定特定的亚组
基于分子生物标志物和/或肿瘤特征,
新的治疗策略,包括靶向药物。一个重要的,长期的,
这一概念的核心是乳腺恶性肿瘤亚组对雌激素受体的依赖性
(ER)以及ER信号传导轴。在这方面,有一个亚组的妇女与ER+管腔
B人乳腺恶性肿瘤,由于以下发展而表现出显著的复发风险:
对内分泌治疗的抵抗,包括他莫昔芬。为了解决这个问题,
确定导致内分泌治疗耐药的途径或分子机制。一
癌症医学的第二个重要主题是基于“癌基因成瘾”的想法,
这一现象意味着,虽然肿瘤含有多种遗传,表观遗传,信号传导和代谢,
尽管这种肿瘤的复杂性,细胞的生长和存活往往会受到损害,
单个驱动基因/蛋白质的靶向。
因此,癌基因成瘾现象
在
特定的癌症,包括腔B乳腺癌,提供了一个科学的理由,以确定
致癌的驱动程序的过程中管腔B耐药的内分泌疗法。代谢压力,
由于异常的活性氧ROS水平,是癌症的标志,
导致致癌附加样表型的生理学和代谢,以及对
内分泌治疗基于这些观察,提出K68乙酰化(K68-Ac)
促进一种新发现的MnSOD单体形式,与已建立的ROS不同
四聚MnSOD的解毒作用,重新编程细胞和线粒体代谢,
致癌和肿瘤抗性表型。最后,将针对MnSOD-K68-Ac轴,使用
化学MnSOD模拟物(GC 4419),将内分泌抗性肿瘤转化为敏感表型?
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Gius其他文献
David Gius的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Gius', 18)}}的其他基金
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
由于 MnSOD 生物学的破坏,谱系可塑性驱动了对电离辐射/雄激素剥夺疗法的抵抗
- 批准号:
10737810 - 财政年份:2021
- 资助金额:
$ 5.07万 - 项目类别:
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
由于 MnSOD 生物学的破坏,谱系可塑性驱动了对电离辐射/雄激素剥夺疗法的抵抗
- 批准号:
10533472 - 财政年份:2021
- 资助金额:
$ 5.07万 - 项目类别:
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
由于 MnSOD 生物学的破坏,谱系可塑性驱动了对电离辐射/雄激素剥夺疗法的抵抗
- 批准号:
10390451 - 财政年份:2021
- 资助金额:
$ 5.07万 - 项目类别:
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies
MnSOD-K68-Ac 重新编程 ER 乳腺恶性肿瘤中的谱系可塑性开关/干性
- 批准号:
10327336 - 财政年份:2021
- 资助金额:
$ 5.07万 - 项目类别:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
MnSOD-Ac-ROS-HIF2a 轴的失调促进 IR/顺铂耐药表型
- 批准号:
10335424 - 财政年份:2021
- 资助金额:
$ 5.07万 - 项目类别:
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies
MnSOD-K68-Ac 重新编程 ER 乳腺恶性肿瘤中的谱系可塑性开关/干性
- 批准号:
10541193 - 财政年份:2021
- 资助金额:
$ 5.07万 - 项目类别:
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
由于 MnSOD 生物学的破坏,谱系可塑性驱动了对电离辐射/雄激素剥夺疗法的抵抗
- 批准号:
10548835 - 财政年份:2021
- 资助金额:
$ 5.07万 - 项目类别:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
MnSOD-Ac-ROS-HIF2a 轴的失调促进 IR/顺铂耐药表型
- 批准号:
10024964 - 财政年份:2017
- 资助金额:
$ 5.07万 - 项目类别:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
MnSOD-Ac-ROS-HIF2a 轴的失调促进 IR/顺铂耐药表型
- 批准号:
9889066 - 财政年份:2017
- 资助金额:
$ 5.07万 - 项目类别:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
MnSOD-Ac-ROS-HIF2a 轴的失调促进 IR/顺铂耐药表型
- 批准号:
9262705 - 财政年份:2017
- 资助金额:
$ 5.07万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 5.07万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 5.07万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 5.07万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 5.07万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 5.07万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 5.07万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 5.07万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 5.07万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 5.07万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 5.07万 - 项目类别:
Research Grant